GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH)

Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes

Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239

Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease

Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604

Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis

Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327

Mechanisms of Insulin Action and Insulin Resistance

Petersen, M. C., & Shulman, G. I. (2018) · Physiological Reviews · doi:10.1152/physrev.00063.2017 · Cited by 3,028

Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease

Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987

Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up

Ekstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., & Hultcrantz, R. (2015) · Hepatology · doi:10.1002/hep.27368 · Cited by 2,287

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebo-controlled trial

Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237

Fibrosis Progression in Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-analysis of Paired-Biopsy Studies

Singh, S., Allen, A. M., Wang, Z., Prokop, L. J., Murad, M. H., & Loomba, R. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.04.014 · Cited by 1,748

Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease

Lambert, J. E., Ramos–Roman, M. A., Browning, J. D., & Parks, E. J. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.11.049 · Cited by 1,069 · cited 1×

Loss of transketolase promotes the anti-diabetic role of brown adipose tissues

Ji, Y., Liu, W., Zhu, Y., Li, Y., Lu, Y., Liu, Q., Tong, L., Hu, L., Xu, N., Chen, Z., et al. (2022) · Journal of Endocrinology · doi:10.1530/joe-22-0047 · Cited by 7

A combined transcriptomics and proteomics approach to reveal the mechanism of AEE relieving hyperlipidemia in ApoE-/- mice

Lu, X.-R., Tao, Q., Qin, Z., Liu, X., Li, S., Bai, L., Ge, W.-B., Liu, Y.-X., Li, J., & Yang, Y. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116400 · Cited by 7

Bioactive Compounds from Lactic Acid Bacterial (LAB) Fermented Products Modulate Metabolic Parameters and mRNA Expression of Adipogenic and Inflammatory Genes in Obese Mice

Hisham, A. A., Islam, M. M., Shah, S. T., Mamun, A. A., & Hossain, M. S. (2025) · ACS Food Science & Technology · doi:10.1021/acsfoodscitech.5c00087 · Cited by 7

Hepatic Inactivation of Carnitine Palmitoyltransferase 1a Lowers ApoB-Containing Lipoproteins in Mice

Helsley, R. N., Zelows, M. M., Noffsinger, V. P., Anspach, G., Dharanipragada, N., Mead, A. E., Cobo, I., Carter, A., Wu, Q., SHALAUROVA, I. Y., et al. (2025) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.125.322473 · Cited by 6

Exploring hepatic stellate cell-driven fibrosis: therapeutic advances and future perspectives

Singh, A., Akhtar, A., & Shukla, P. (2025) · ADMET & DMPK · doi:10.5599/admet.2874 · Cited by 7

Pharmacokinetics, mass balance, metabolism, and excretion of the liver-targeted acetyl-CoA carboxylase inhibitor PF-05221304 (clesacostat) in humans

Ryder, T. F., Bergman, A. J., King‐Ahmad, A., Amin, N. B., Lall, M. S., Ballard, T. E., & Kalgutkar, A. S. S. (2022) · Xenobiotica · doi:10.1080/00498254.2022.2062487 · Cited by 9

Bempedoic acid as a PPARα activator: New perspectives for hepatic steatosis treatment in a female rat experimental model

Bentanachs, R., Velázquez, A. M., Sánchez, R. M., Alegret, M., Laguna, J. C., & Roglans, N. (2022) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2022.03.001 · Cited by 7

Herbal mixture of Platycodon grandiflorum, Cinnamomum cassia, and Asiasarum sieboldii extracts protects against NASH progression via regulation of hepatic steatosis, inflammation, and apoptosis

Zhang, S., Lee, H., Ahn, H. R., Kim, H., Yang, H. O., Yoo, K., Lee, G., & Kim, J. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.157077 · Cited by 6

Future potential therapeutics to treat MASH

Mahajan, S., Malladi, N., & Banerjee, S. K. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104451 · Cited by 7

Gan-jiang-ling-zhu decoction improves steatohepatitis by regulating gut microbiota-mediated 12-tridecenoic acid inhibition

Xu, R., Wu, J., Pan, J., Zhang, S., Yang, Y., Zhang, L., Zhou, W., Wu, N., Hu, D., Ji, G., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1444561 · Cited by 6

El ácido bempedoico como activador PPARα: Nuevas perspectivas para el tratamiento de la esteatosis hepática en un modelo experimental de rata hembra

Bentanachs, R., Velázquez, A. M., Sánchez, R. M., Alegret, M., Laguna, J. C., & Roglans, N. (2021) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2021.09.004 · Cited by 6

Aryl Hydrocarbon Receptor Activation Limits the Fatty Acid Synthesis and Subsequent “miR-193a-3p-HDAC3-FASN” Signals to Alleviate Intestinal Fibrosis

Wu, X., Miao, X., Xue, X., Qiao, S., Dai, Y., & Wei, Z. (2024) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.4c00976 · Cited by 5

Platelets in the regulation of glucose and lipid metabolism—functions beyond the maintenance of vascular integrity are being revealed

Kolczyńska, K., Kassouf, T., Stegner, D., & Sumara, G. (2025) · FEBS Journal · doi:10.1111/febs.70198 · Cited by 5

From lipid function to dysfunction: Very long-chain fatty acids as emerging regulators of neuroinflammatory pathways

Sahu, R. K., Yang, Y., & Chung, H.-L. (2026) · iScience · doi:10.1016/j.isci.2026.114724 · Cited by 5

Oyster hydrolysate ameliorates ethanol diet‐induced alcoholic fatty liver by regulating lipid metabolism in rats

Byun, J., Shin, J., Choi, Y. J., & Choung, S. (2021) · International Journal of Food Science & Technology · doi:10.1111/ijfs.14983 · Cited by 5

Emerging Therapies for Non-Alcoholic Steatohepatitis (NASH): A Comprehensive Review of Pharmacological and Non-Pharmacological Approaches

Kakde, S. P., Mushtaq, M., Liaqat, M., Ali, H., Mushtaq, M. M., Sarwer, M. A., Ullah, S., Hassan, M. W., Khalid, A., & Bokhari, S. F. H. (2024) · Cureus · doi:10.7759/cureus.69129 · Cited by 7

Diverting hepatic lipid fluxes with lifestyles revision and pharmacological interventions as a strategy to tackle steatotic liver disease (SLD) and hepatocellular carcinoma (HCC)

Misceo, D., Mocciaro, G., D’Amore, S., & Vacca, M. (2024) · Nutrition & Metabolism · doi:10.1186/s12986-024-00871-3 · Cited by 6

Immunometabolic factors contributing to obesity-linked hepatocellular carcinoma

Akl, M. G., & Widenmaier, S. B. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.1089124 · Cited by 6

Human skin stem cell-derived hepatic cells as in vitro drug discovery model for insulin-driven de novo lipogenesis

Buyl, K., Vrints, M., Fernando, R. N., Desmae, T., Eeckhoutte, T. V., Jans, M., van der Schueren, J., Boeckmans, J., Rodrigues, R. M., Boe, V. D., et al. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175989 · Cited by 5

Beyond the liver: targeting the hepatic microenvironment and multi-organ networks for innovative MASH therapy

Fu, R., Zhang, F., Fu, J., Li, Y., Zhu, X., Ding, Q., & Zhu, Y. Z. (2025) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2025.163 · Cited by 6

Triggering compensatory growth by completely replacing fishmeal with novel protein sources in the diets of juvenile largemouth bass (Micropterus salmoides): Effects on growth performance and liver health

Wang, Y., Li, L., Huang, Y., & Wang, C. (2025) · Aquaculture and Fisheries · doi:10.1016/j.aaf.2025.03.001 · Cited by 4

AN1284 attenuates steatosis, lipogenesis, and fibrosis in mice with pre-existing non-alcoholic steatohepatitis and directly affects aryl hydrocarbon receptor in a hepatic cell line

Yehezkel, A. S., Abudi, N., Nevo, Y., Benyamini, H., Elgavish, S., Weinstock, M., & Abramovitch, R. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1226808 · Cited by 4

Repurposing a human acetyl-CoA carboxylase inhibitor firsocostat to treat fungal candidiasis alone and in combination

Chen, T., Yao, J., Quan, K., Xu, J., Hang, X., Tong, Q., Liu, G., Luo, P., Zeng, L., Feng, G., et al. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01131-23 · Cited by 5

The pharmacological management of alcohol-related cirrhosis: what’s new?

Verma, N., Vinod, A. P., & Singal, A. K. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2409941 · Cited by 4

Phytochemical and biological studies on rare and endangered plants endemic to China. Part XLIV. Integrated NMR/EI-MS/LC-PDA-ESIMS approach for dereplication and targeted isolation of fortunefuroic acids from Keteleeria fortunei across diverse geographical origins

Zhao, Z., Jiang, Z., Tong, Y., Chi, C., Zang, Y., Choo, Y., Xiong, J., Li, J. X., & Hu, J. (2025) · Phytochemistry · doi:10.1016/j.phytochem.2025.114453 · Cited by 4

Advances and Emerging Therapies in the Treatment of Non-alcoholic Steatohepatitis

Brennan, P. N., The University of Edinburgh, C. F. R. M., NHS Tayside, N. H. A. M. S., The University of Dundee, D. O. M. A. C. M., Dillon, J. F., NHS Tayside, N. H. A. M. S., The University of Dundee, D. O. M. A. C. M., McCrimmon, R., NHS Tayside, N. H. A. M. S., & The University of Dundee, D. O. M. A. C. M. (2022) · European Endocrinology · doi:10.17925/ee.2022.18.2.148 · Cited by 3

Isotype-selective roles of hepatic acetyl-CoA carboxylases in a mouse model of fatty liver disease

Beretta, M., Vancuylenburg, C. S., Shrestha, R., Olzomer, E. M., Osborne, B., Zhou, M., Zhang, S., Hargreaves, A., Byrne, F. L., & Hoehn, K. L. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102264 · Cited by 3

Quick glance at 'metabolic dysfunction associated steatotic liver disease' therapeutics: Targets, trials, and trends

Zacharia, G. S., Ashraf, M. H., Sosa, F., Jacob, A., & Patel, H. (2025) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v16.i4.110827 · Cited by 3

Targeting Fatty Acids in Liver Cancer: Molecular Insights and Drug Approaches

Cigliano, A., Pischedda, D., Pandino, C., Galleri, G., & Calvisi, D. F. (2026) · Biomolecules · doi:10.3390/biom16020329 · Cited by 3

A Collection of Novel Antitumor Agents That Regulate Lipid Metabolism in the Tumor Microenvironment

Zhang, J., Xu, S., Yue, L., Lei, H., & Zhai, X. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02809 · Cited by 3

Discovery of small molecule ACC inhibitors: Potential treatment for excessive sebum secretion

Feng, X., Luo, X., Niu, X., Wang, S., Feng, M., Jiang, X., Chen, W., & Bai, R. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108438 · Cited by 3

Drug treatments to prevent first decompensation in cirrhosis

Kezer, C. A., Berzigotti, A., Fortune, B. E., & Simonetto, D. A. (2024) · Hepatology · doi:10.1097/hep.0000000000001117 · Cited by 3

Network pharmacology and transcriptomics reveal complanatoside A regulates lipid metabolism in hyperlipidemia and nonalcoholic fatty liver disease via the AMPK pathway

Jiang, S., Liang, Z., Ma, J., Li, Y., Fan, X., Qiao, Z., Wang, Z., Shen, Y., Le, F., & Wang, J. (2025) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2025.109960 · Cited by 3

Convergent Syntheses of Isomeric Imidazolospiroketones as Templates for Acetyl-CoA Carboxylase (ACC) Inhibitors

Limberakis, C., Smith, A. C. T., Bagley, S. W., Yayla, H. G., Kung, D. W., & Griffith, D. A. (2023) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.3c01374 · Cited by 2

A microvascularized in vitro liver model for disease modeling and drug discoveryPreprint

Bonanini, F., Dinkelberg, R., Torregrosa, M. C., Kortekaas, N., Hagens, T. M. S., Treillard, S., Kurek, D., van Duinen, V., Vulto, P., & Bircsak, K. M. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.07.05.602196 · Cited by 2

ND-630, an acetyl-CoA carboxylase inhibitor, prevents renal fibrosis in adenine-induced CKD mice

Liu, X., Yu, P., Wu, S., Xu, Y., Ye, X., & Lu, J. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04553-6 · Cited by 1

Fatty acid synthesis supports tumor progression through facilitating the activity of TORC1 signaling

Károlyi, D., Botor, B. S., Neuhauser, N., Rubics, A., Szinyákovics, J., Kovács, T., Péter, M., Balogh, G. E., O’Farrell, F., & Takáts, S. (2026) · Cell Death and Disease · doi:10.1038/s41419-026-08738-6 · Cited by 1

Significance of Lipid Metabolism Reprogramming in Tumor Microenvironment and Development of Novel Therapeutic Intervention

Mondal, P., & Bhattacharyya, S. (2026) · Cell Biochemistry and Function · doi:10.1002/cbf.70215 · Cited by 1

Reductive death is averted by a conserved de novo lipogenic switch

Ahsan, F. M., Rotti, J. F., Yerevanian, A. I., Emans, S. W., Stuhr, N. L., Aceves-Salvador, J. A., Wang, W., Baker, D. J., Pouli, D., Skinner, O. S., et al. (2026) · Molecular Cell · doi:10.1016/j.molcel.2026.05.011 · Cited by 4

A multi-functional oral small molecule targeting energy and lipid metabolism to treat obesity and related metabolic disorders

Lee, J. Y., Zhu, C., Boldridge, M. A., Stark, R. L., Bonilla, G. M., Watari, K., Papa, C., Xu, L., Gonzãlez, F., Tang, X., et al. (2026) · Science Advances · doi:10.1126/sciadv.aed3119 · Cited by 1

Metabolic Targets in Nonalcoholic Steatohepatitis: Treating the Disease at the Metabolic Root

Aggarwal, P., Singh, T., & Alkhouri, N. (2020) · Current Hepatology Reports · doi:10.1007/s11901-020-00533-x · Cited by 1

The Impact of Carbohydrate Restriction and Nutritional Ketosis on Cardiovascular Health

Lowe, D. A., Corbit, K. C., & Weiss, E. J. (2021) · Contemporary cardiology · doi:10.1007/978-3-030-78177-4_5 · Cited by 1

Efficacy and safety of acetyl-CoA carboxylase (ACC) inhibitors in the treatment of nonalcoholic steatohepatitis (NASH): A protocol for systematic review

Xu, L., Yang, H., Xu, H., Yang, R., Fen, L., Jiang, D., Xu, L., & Xing, Y. (2022) · Medicine · doi:10.1097/md.0000000000032357 · Cited by 1

Emerging drugs for the treatment of hepatic fibrosis on nonalcoholic steatohepatitis

Iwaki, M., Yoneda, M., Wada, N., Otani, T., Kobayashi, T., Nogami, A., Saito, S., & Nakajima, A. (2024) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2024.2328036 · Cited by 1

[Translated article] Common Approach to Metabolic-Associated Fatty Liver Disease in Patients With Psoriasis: Consensus-Based Recommendations From a Multidisciplinary Group of Experts

Carrascosa, J. M., Vilarrasa, E., Belinchón, I., Herranz, P., Crespo, J., Guimerá, F., & Olveira, A. (2023) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2023.04.013 · Cited by 1

Acetyl-CoA metabolism drives epigenome change and contributes to carcinogenesis risk in fatty liver diseasePreprint

Assante, G., Chandrasekaran, S., Ng, S., Tourna, A., Chung, C. H., Isse, K. A., Filippi, C., Dhawan, A. K., Liu, M., Rozen, S., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.07.22.453333 · Cited by 1

Biocatalytic Resolutions

Clayman, P. D., Roiban, G., & Fuerst, D. E. (2023) · Elsevier eBooks · doi:10.1016/b978-0-32-390644-9.00058-5

Additional file 4 of Acetyl-CoA metabolism drives epigenome change and contributes to carcinogenesis risk in fatty liver disease

Assante, G., Chandrasekaran, S., Ng, S., Tourna, A., Chung, C. H., Isse, K. A., Banks, J. L., Soffientini, U., Filippi, C., Dhawan, A. K., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20153149

Additional file 3 of Acetyl-CoA metabolism drives epigenome change and contributes to carcinogenesis risk in fatty liver disease

Assante, G., Chandrasekaran, S., Ng, S., Tourna, A., Chung, C. H., Isse, K. A., Banks, J. L., Soffientini, U., Filippi, C., Dhawan, A. K., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20153146

Additional file 1 of Acetyl-CoA metabolism drives epigenome change and contributes to carcinogenesis risk in fatty liver disease

Assante, G., Chandrasekaran, S., Ng, S., Tourna, A., Chung, C. H., Isse, K. A., Banks, J. L., Soffientini, U., Filippi, C., Dhawan, A. K., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20153140

Impact of Dapagliflozin on Hepatic Lipid Metabolism and a Dynamic Model of Ketone Body Levels

Wan, Z., Yuan, M., Liu, Z., Cai, Y., He, H., & Hao, K. (2025) · The AAPS Journal · doi:10.1208/s12248-025-01024-x

Targeting PKLR and lipogenic enzymes through JNK inhibition to develop a therapeutic strategy for MASLD and MASHPreprint

Mardinoğlu, A., Kim, W., Li, M., Liao, X., Özmen, S., Yıldız, E., Saraçoğlu, M., Baba, C., Çelikezen, F. Ç., Atalay, S. A., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-7114368/v1

Additional file 1 of Liraglutide attenuates type 2 diabetes mellitus-associated non-alcoholic fatty liver disease by activating AMPK/ACC signaling and inhibiting ferroptosis

Guo, T., Yan, W., Cui, X., Liu, N., Wei, X., Sun, Y., Fan, K., Liu, J., Zhu, Y., Wang, Z., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26620690

Additional file 1 of Nicotinate-curcumin improves NASH by inhibiting the AKR1B10/ACCα-mediated triglyceride synthesis

Lin, X.-L., Zeng, Y.-L., Ning, J., Cao, Z., Bu, L.-L., Liao, W.-J., Zhang, Z.-M., Zhao, T.-J., Fu, R.-G., Yang, X.-F., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26122581

Additional file 2 of Acetyl-CoA metabolism drives epigenome change and contributes to carcinogenesis risk in fatty liver disease

Assante, G., Chandrasekaran, S., Ng, S., Tourna, A., Chung, C. H., Isse, K. A., Banks, J. L., Soffientini, U., Filippi, C., Dhawan, A., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20153143

Additional file 1 of Metabolic convergence on lipogenesis in RAS, BCR-ABL, and MYC-driven lymphoid malignancies

Liefwalker, D. F., Ryan, M., Wang, Z., Pathak, K. V., Plaisier, S. B., Shah, V., Babra, B., Dewson, G. S., Lai, I. K., Mosley, A. R., et al. (2021) · Figshare · doi:10.6084/m9.figshare.15179621

Antitumor Activity of the ACC Inhibitor Firsocostat in Breast Cancer Cell Lines: A Proof-of-Concept In Vitro Study

Picerno, S., Giglio, E., Giuseffi, M., Radino, M., Sichetti, M., & Mecca, M. (2026) · Pharmaceuticals · doi:10.3390/ph19020201

Autophagy in the interplay between shear stress and kidney epithelium homeostasis

Roccio, F. (2021) · theses.fr (ABES) · doi:10.70675/899d5d97z1062z453cza091zcae756198817

Design and evaluation of therapeutic particles modulating autophagy

Zagkou, S. (2021) · theses.fr (ABES) · doi:10.70675/945352cczdaf3z45fczb8dezdc79d3ca5100

Advances in Diagnostic and Therapeutic Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease

Njeim, R., Abureesh, O., Sohail, A., Tam, R., & Deeb, L. S. (2026) · Livers · doi:10.3390/livers6030035

Targeting PKLR and lipogenic enzymes through JNK inhibition to develop a therapeutic strategy for MASLD and MASH

Kim, W., Li, M., Liao, X., Özmen, S., Yıldız, E., Saraçoğlu, M., Baba, C., Çelikezen, F. Ç., Atalay, S. A., Akkuş, A. T., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1823203

Ganoderic acid A alleviates metabolic dysfunction-associated fatty liver disease through attenuating steatosis and cellular apoptosis by targeting acetyl-CoA carboxylase

Yao, Y., Liu, Z. H., Wang, X., Bian, C., Yin, N., Peng, X., Qin, S., Wang, R., & Zhang, Y. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.117108

Crosstalk Between Immunometabolic Pathways in Non-Small Cell Lung Cancer

Khilwani, R., Gulhane, P., Tukrul, M., Rani, D., Kumar, G., Goswami, S., & Singh, S. (2026) · Immunological Investigations · doi:10.1080/08820139.2026.2698754

Combination pharmacotherapy for MASH: Potential synergistic approaches

Meije, D. A., Holleboom, A. G., & van de Graaf, S. F. J. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118492

Lipotoxicity in MAFLD/MASH: cellular mechanisms and targetable nodes

Tawai, J., Zhou, K., & Xiong, J. (2026) · Targetome · doi:10.48130/targetome-0026-0047

BindingDB Entry 50022926: A Collection of Novel Antitumor Agents That Regulate Lipid Metabolism in the Tumor Microenvironment.

BindingDB (2026) · UC San Diego · doi:10.7270/q20g3r14

BindingDB Entry 50013072: Synthesis and in vitro evaluation of novel spiroketopyrazoles as acetyl-CoA carboxylase inhibitors and potential antitumor agents.

BindingDB (2022) · UC San Diego · doi:10.7270/q2gx4g85

Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis

Lawitz, E. J., Coste, A., Poordad, F., Alkhouri, N., Loo, N., McColgan, B. J., Tarrant, J. M., Nguyen, T., Han, L., Chung, C., et al. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.04.042 · Cited by 217

GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease

Loomba, R., Kayali, Z., Noureddin, M., Ruane, P., Lawitz, E. J., Bennett, M., Wang, L., Harting, E., Tarrant, J. M., McColgan, B. J., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.07.027 · Cited by 340

Acetyl-CoA carboxylase inhibitor increases LDL-apoB production rate in NASH with cirrhosis: prevention by fenofibrate

Dandan, M., Han, J., Mann, S., Kim, R., Li, K. W., Mohammed, H., Chuang, J.-C., Zhu, K., Billin, A. N., Huss, R. S., et al. (2023) · Journal of Lipid Research · doi:10.1016/j.jlr.2023.100339 · Cited by 18

New avenues for NASH therapy by targeting ACC

Bian, H., Liu, Y.-M., & Chen, Z. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.01.001 · Cited by 19

Combinations of an acetyl CoA carboxylase inhibitor with hepatic lipid modulating agents do not augment antifibrotic efficacy in preclinical models of NASH and fibrosis

Vijayakumar, A., Ökesli, A., Wang, T., Olson, I. A., Seung, M., Kusam, S., Hollenback, D., Mahadevan, S., Marchand, B., Toteva, M. M., et al. (2022) · Hepatology Communications · doi:10.1002/hep4.2011 · Cited by 14